Tellgen(SZ:300642)2025-04-29 12:48Financial Performance - In Q1 2025, the company achieved revenue of 74.89 million yuan, a year-on-year decrease of 19.53%, primarily due to industry policy impacts and reduced HPV usage from price-sensitive ICL customers [4] - The company maintained a gross margin stability through cost control measures, resulting in a notable recovery in net profit for Q1 2025 compared to the previous year [5] Asset Management - The company recognized asset impairment provisions totaling 5.59 million yuan in Q1 2025, which reduced net profit by 4.75 million yuan [6] - The largest impact on impairment provisions came from bad debt losses on accounts receivable, which had a year-end balance of 211 million yuan [6] Equipment Installation and Market Strategy - The installation pace of flow cytometers and chemiluminescence analyzers in Q1 2025 was significantly faster than the same period last year, with plans to maintain this momentum [7] - The introduction of the small automated chemiluminescence immunoassay analyzer TESMI i50 is expected to enhance market penetration in large hospitals and grassroots healthcare facilities [8] Revenue Structure - The main customer sources remain hospitals, ICL, and health examination centers, with potential growth in grassroots hospitals due to the promotion of TESMI i50 and non-collection projects [9] - Immunoassay reagents continue to be the primary revenue source, with a decline in tumor marker revenue but an expected increase in hormone product revenue; methylation products, particularly lung cancer methylation, showed significant growth compared to the previous year [9]